Preparation for colloidal gold immunochromatography development

Establishment of Guangzhou Weimi Bio-tech Co., Ltd. (referred to as Weimi Bio-tech) in September

Officially settled in South China New Materials Innovation Park in December

Obtained Medical Device Manufacturing Enterprise License in January

Completed the development and QMS audit of four colloidal gold products

Completed the type tests of four products and clinical studies in two hospitals in July

Preparation for dry chemistry method development in August

Preparation for time-resolved fluorescence immunochromatography development in January

Completed the formal production of 3 lots of FOBTF and GBS and placed them on the market in

The development and type tests of 14 new products completed in June

Completed the clinical studies and registration submission for 14 new products in January

Secured Guangzhou special fund for industry-academia-research collaborative innovation by bringing together enterprises, academia, and research institutes (with Guangdong Academy of Agricultural Sciences) in May

Type tests of A and B product families completed by Beijing Institute of Medical Device Testing in July

2 invention patents and 6 utility model patents authorized in August

Obtained new high-tech product designation for 10 products in January

Obtained one Class II medical device registration certificate (in vitro diagnostic reagent) in April

Completed the formal production of the first batch of SAA, PCT and placed them on the market in May

Completed the change registration of clinical samples used for 7 quantitative reagents in May

Production capacity increased to 250,000 tests per month in January

Annual meeting in March

Preparation for medical device registration in March

Completed type tests of 4 biochemistry tests

In January, a large annual meeting as well as a three-day external training for middle and top management were held, and 22 Class I tests were filed with competent authority

1 utility model patent and 1 invention patent were accepted in April

Establishment of foreign trade department to export products, and a wholly-owned subsidiary Changsha Weimi Biotech Co., Ltd. in February

Started the development of COVID-19 test in February and the project got checked and accepted in May

Preparation for molecular diagnostics development in June

Obtained brand certification of 4 stars in January

Shanghai Yitu Enterprise Management Partnership Corporate (limited partnership) became a shareholder of Weimi Biotech in March

Built a practice teaching base with Guangzhou University of Chinese Medicine in March Office, production, and development expansion in Guangzheng Science and Technology Industrial Park completed in April

Appeared in the list of “China Future Healthcare Rankings 2021 TOP100 Medical Devices Companies" once again in April

Newly received 3 utility model patents in May-July

Won the title of "2020 Guangdong Provincial Abide by Contract and Value Credit Enterprise" In June

"Guangdong Provincial Engineering Technology Research Center" qualified in August

Completed B round financing of over 100 million yuan in October

Incubated by Guangzhou “Professional, Refined, Unique and Novel" private enterprise supporting program in October

New website officially launched in October